
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings exhibits a robust outlook supported by a 5% increase in RFP flow across all market segments, with particularly strong performance in the EBP segment, indicating a healthy demand environment. The company anticipates capital deployment of $2 billion in 2025 for mergers and acquisitions as well as share repurchases, reflecting confidence in its strategic growth trajectory. Additionally, a 5.5% growth in NTM backlog at constant foreign exchange rates suggests a positive trend in new business, likely contributing to accelerated revenue growth in the research and development services segment.
Bears say
The negative outlook on IQVIA Holdings Inc. is primarily driven by a combination of adverse macroeconomic factors, including a prolonged impact from COVID-19 and rising interest expenses, which have hampered investor sentiment and earnings per share (EPS) growth since the first quarter of 2022. Additionally, a flat backlog due to foreign exchange headwinds and a significant downward adjustment of approximately $500 million has further contributed to concerns about future revenue generation capabilities. The company's gross margin has experienced a decline, attributed to revenue mix issues and stranded costs from delayed trials, which, alongside a challenging funding environment in the biopharma sector, suggests that growth expectations will remain suppressed, leading to potential EPS deterioration and valuation compression.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares